HC Wainwright Has Bullish Estimate for HeartBeam Q2 Earnings

HeartBeam, Inc. (NASDAQ:BEAT) – Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for HeartBeam in a note issued to investors on Friday, May 22nd. HC Wainwright analyst Y. Chen now forecasts that the medical research company will post earnings of ($0.11) per share for the quarter, up from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.31) EPS.

A number of other equities analysts also recently weighed in on BEAT. Wall Street Zen raised shares of HeartBeam from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. D. Boral Capital lowered HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. Benchmark lowered their price target on HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating for the company in a research report on Friday, May 15th. Finally, B. Riley Financial assumed coverage on HeartBeam in a research note on Tuesday, March 31st. They set a “buy” rating and a $4.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.33.

HeartBeam Price Performance

BEAT opened at $0.89 on Wednesday. HeartBeam has a 12 month low of $0.54 and a 12 month high of $4.00. The business has a 50-day moving average of $1.03 and a two-hundred day moving average of $1.47. The stock has a market capitalization of $49.58 million, a price-to-earnings ratio of -1.59 and a beta of -0.86.

HeartBeam (NASDAQ:BEAT) last released its earnings results on Wednesday, May 13th. The medical research company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Insider Activity at HeartBeam

In related news, Director Mark E. Strome acquired 750,000 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were bought at an average cost of $0.80 per share, with a total value of $600,000.00. Following the completion of the transaction, the director directly owned 3,650,000 shares of the company’s stock, valued at $2,920,000. This trade represents a 25.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Ferrari bought 62,500 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was bought at an average cost of $0.80 per share, with a total value of $50,000.00. Following the transaction, the director directly owned 291,636 shares of the company’s stock, valued at approximately $233,308.80. This trade represents a 27.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 1,118,750 shares of company stock worth $895,000. Corporate insiders own 18.04% of the company’s stock.

Institutional Trading of HeartBeam

A number of hedge funds have recently made changes to their positions in the company. Clarity Financial LLC purchased a new position in shares of HeartBeam in the fourth quarter valued at $25,000. CIBC Private Wealth Group LLC purchased a new stake in HeartBeam during the 4th quarter worth $26,000. Truist Financial Corp acquired a new position in HeartBeam in the 4th quarter worth $36,000. Bessemer Group Inc. purchased a new position in HeartBeam in the 3rd quarter valued at about $25,000. Finally, Jane Street Group LLC purchased a new position in HeartBeam in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 7.77% of the company’s stock.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.